1. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model
   Yuki Fujii et al, 2021, Investigational New Drugs CrossRef
2. A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients with Esophageal Adenocarcinoma
   Alexander J. Byun et al, 2023, Annals of Surgery CrossRef
3. Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment
   Qiuhong Chen et al, 2024, Discover Oncology CrossRef
4. A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach
   Hoda T. Amer et al, 2022, Frontiers in Molecular Biosciences CrossRef
5. The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets
   Giovanna Giordano et al, 2022, Cancers CrossRef
6. Mesothelin‑specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3‑treated self‑differentiated dendritic cells
   Niphat Jirapongwattana et al, 2022, Oncology Reports CrossRef
7. Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
   Teifion Luckett et al, 2024, Cancer Research CrossRef
8. Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential
   Diego F. Chamorro et al, 2023, Cancers CrossRef